Study of CD19CD20-CAR-T for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 75 years old.
- You have been diagnosed with a type of B-cell lymphoma that has relapsed (come back) or is refractory (did not respond to treatment).
- You have tried at least two standard treatment plans before.
- Your tumor cells show a marker called CD20.
- You are able to donate blood cells through a process called apheresis.
- You have not had any treatment with antibodies or other cell therapies (like CAR-T) before (except possibly low-CD19 CAR-T).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy that targets two markers (CD19 and CD20) on your lymphoma cells. It is for people whose lymphoma came back or didn't respond to previous treatments, including CD19 CAR-T therapy.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.